Advertisement

Spotlight Series on Hepatitis C

International News

Bristol-Myers Halts Hepatitis C Drug Study on "Serious" Safety Issue

August 2, 2012

Citing the "emergence of a serious safety issue," Bristol-Myers Squibb Co. said Wednesday it was voluntarily suspending the Phase II study of a hepatitis C drug candidate, BMS-986094. Earlier this year, BMS paid $2.5 billion to acquire Inhibitex Inc., the company that developed the nucleotide polymerase inhibitor formerly known as INX-189. "The cause of the safety issue and any potential relationship to the study drug are unknown at this time," BMS said in a statement. The company currently is assessing all the study patients and will decide on next steps following an evaluation of patient data.

Back to other news for August 2012

Adapted from:
Wall Street Journal
08.02.2012; Saabira Chaudhuri




This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.



MOST VIEWED ARTICLES